68Ga-DOTA-WL12 PET/CT Outperforms FDG for Predicting Chemo-Immunotherapy Response in HNSCC

Pre-treatment 68Ga-DOTA-WL12 PET outperformed 18F-FDG PET for predicting programmed death-ligand 1 (PD-L1) expression (AUC 0.92 vs 0.69) and chemo-immunotherapy response (responder SUVmax 2.7 vs non-responder 1.3; independent predictor OR 12.42) in head and neck squamous cell ca…

• In lesion-based analysis (37 lesions), 68Ga-DOTA-WL12 SUVmax was higher in PD-L1-positive vs negative lesions (2.7 vs 1.7, p<0.001), with AUC 0.92 vs 0.69 for FDG (p=0.003).
• Among 17 patients receiving chemo-immunotherapy, 68Ga-DOTA-WL12 SUVmax was the only independent predictor of response (OR 12.42, 95% CI 2.08–74.15, p=0.006).
• 18F-FDG PET/CT metrics could not discriminate PD-L1 status or treatment response.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.